Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STOP-RECUR: Sirolimus and Prednisone for Coronary In-stent Restenosis
NCT06981845Not yet recruiting
- Sponsor
- National Center for Cardiovascular Disease
- Start
- Jun 2025
- Primary completion
- Jun 2028
- Modality
- Orthosteric Ligands
01
Overview
Randomised, double-blind trial of prednisone and sirolimus in coronary in-stent restenosis (ISR) (2 arms), sponsored by National Center for Cardiovascular Disease. Primary endpoint: Target Vessel Failure at 1 year. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
prednisonesirolimus
03
Conditions
coronary in-stent restenosis (ISR)
Beyond the preview
Go deeper on NCT06981845.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06981845.